Nerve stimulation reduces impact of migraine
A pilot study has shown that non-invasive vagus nerve stimulation (nVNS) reduced the number of headache days per month for chronic migraine patients.
Read More
Author: Hugh Gosling
NICE approves Servier’s Lonsurf as third-line cancer therapy
The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic colorectal cancer.
Read More
June issue of PharmaTimes – out now
Read the June issue of PharmaTimes now – digital and online.
Read MoreEngland’s pledge to recruit more GPs failing
Health secretary Jeremy Hunt’s plans to bring as many 400 doctors from India to the UK are an “admission of failure” of its recruitment policies, says the BMA.
Read MoreEU approval for Revolade for children with rare blood disorder
The European Commission has approved Novartis’ Revolade (eltrombopag) as a first-in-class therapy for children aged one and over with chronic idiopathic thrombocytopenic purpura (ITP) that have not responded to other treatments.
Read More- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
